Pretransplant <i>FLT3</i>-ITD MRD assessed by high-sensitivity PCR-NGS determines posttransplant clinical outcomeSun Loo, Andrew H. Wei, Kelli Gray et al.|Blood|2022Cited by 83
Molecular MRD is strongly prognostic in patients with <i>NPM1</i>-mutated AML receiving venetoclax-based nonintensive therapyJad Othman, Richard Dillon, Ing Soo Tiong et al.|Blood|2023Cited by 65
Venetoclax–based low intensity therapy in molecular failure of <i>NPM1</i>-mutated AMLCarlos Jiménez‐Chillón, Richard Dillon, Jad Othman et al.|Blood Advances|2023Cited by 29
2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working PartyJacqueline Cloos, Michael Heuser, Peter J.M. Valk et al.|Blood|2025Cited by 22
Pretransplant MRD detection of fusion transcripts is strongly prognostic in <i>KMT2A-</i>rearranged acute myeloid leukemiaSun Loo, Andrew H. Wei, Nicola Potter et al.|Blood|2024Cited by 13